Table 1.
Patient demographics and baseline disease characteristics
| Characteristic | Daratumumab 16 mg/kg (n = 32) |
|---|---|
| Age | n = 32 |
| Median (range), years | 56.0 (22–78) |
| < 65 years, n (%) | 24 (75.0) |
| 65–74 years, n (%) | 7 (21.9) |
| ≥ 75, n (%) | 1 (3.1) |
| Sex, n (%) | n = 32 |
| Male | 23 (71.9) |
| Female | 9 (28.1) |
| Asian, n (%) | 32 (100) |
| ECOG PS score, n (%) | n = 32 |
| 0 | 14 (43.8) |
| 1 | 15 (46.9) |
| 2 | 3 (9.4) |
| Median (range) time since diagnosis, months | 24.0 (3.1–185.4) |
| Percentage of CD38 expression | n = 22 |
| Median (range), % | 45.0 (0–100) |
| ≥ 0% to 49%, n (%) | 11 (50.0) |
| ≥ 50%, n (%) | 11 (50.0) |
| H-score of CD38 expression | n = 22 |
| Median (range) | 67.5 (0–300) |
| ≥ 0 to 49, n (%) | 10 (45.5) |
| ≥ 50, n (%) | 12 (54.5) |
| Plasma EBV-DNA, kIU/L | n = 31 |
| Median (range) | 3800.0 (0–11,291,151) |
| β2 microglobulin, mg/L | n = 31 |
| Median (range) | 3.0 (1.7–11.5) |
| Site of disease involvement at initial diagnosis, n (%) | n = 31 |
| Upper aerodigestive tract only | 17 (54.8) |
| Extra-upper aerodigestive tract only | 5 (16.1) |
| Both | 9 (29.0) |
| PINK, n (%) | n = 31 |
| Low | 8 (25.8) |
| Intermediate | 15 (48.4) |
| High | 8 (25.8) |
| PINK-E, n (%) | n = 30 |
| Low | 9 (30.0) |
| Intermediate | 13 (43.3) |
| High | 8 (26.7) |
| Median (range) prior lines of therapy | 2 (1–8) |
| Prior lines of therapy, n (%) | n = 32 |
| 1 | 11 (34.4) |
| 2 | 8 (25.0) |
| ≥ 3 | 13 (40.6) |
| Prior therapies, n (%) | n = 32 |
| L-asparaginase–containing regimen | 27 (84.4) |
| Radiotherapy | 21 (65.6) |
| Cancer-related surgery/procedure | 15 (46.9) |
| Anthracycline-based regimen | 8 (25.0) |
| Autologous stem cell transplant | 4 (12.5) |
EBV, Epstein–Barr virus; ECOG PS, Eastern Cooperative Oncology Group performance status; PINK, prognostic index of natural killer lymphoma; PINK-E, prognostic index for natural killer cell lymphoma–Epstein–Barr virus